A



B

Treatment	SUCRA	PrBest	Mean rank
DPP4i	63.6	11.1	4.6
SU	60.7	6.5	4.9
Met+DPP4i	58.3	16.7	5.2
TZD	58.2	25.0	5.2
Met	57.0	2.4	5.3
Met+TZD	55.4	21.4	5.5
DPP4i+TZD	53.6	4.7	5.6
GLP-1RA	44.1	5.7	6.6
Placebo	43.7	4.8	6.6
DPP4i+SGLT2i	33.8	1.6	7.6
SGLT2i	21.4	0.1	8.9

Supplementary Fig. 6. Network geometry (A), rank test (B), the results of network and pairwise meta-analysis (C) for odds ratios of serious adverse events of antidiabetic treatments. (A) The global test for inconsistency yielded a *P* value of 0.9773, indicating no evidence of inconsistency in the network. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side) and pairwise (lower left side) meta-analytic results are depicted for odds ratios of serious adverse events of antidiabetic treatments. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top-row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonylurea. [a]Results indicate statistical significance.

(*Continued to the next page*)

Supplementary Fig. 6. Continued

C

	DPP4i	SU	Met+DPP4i	TZD	Met	Met+TZD	DPP4i+TZD	GLP-1RA	Placebo	DPP4i+SGLT2i	SGLT2i
DPP4i	DPP4i	0.93 (0.02–50.23)	1.01 (0.02–52.8)	0.85 (0.00–237.5)	0.83 (0.01–46.5)	1.04 (0.00–280.9)	1.33 (0.53–3.35)	1.11 (0.02–62.4)	2.09 (0.04–109.2)	3.34 (0.68–16.4)	5.03[a] (1.06–24.0)
SU		SU	1.08 (0.02–58.7)	0.92 (0.02–52.5)	2.34 (0.04–127.4)	1.12 (0.02–61.4)	1.43 (0.02–85.5)	1.19 (0.45–3.15)	2.24 (0.04–121.2)	3.58 (0.05–262.2)	5.40 (0.07–391.2)
Met+DPP4i	0.99 (0.02–50.1) I^2=0.0% 1 study		Met+DPP4i	0.85 (0.00–236.4)	1.00 (0.02–52.3)	1.03 (0.00–279.6)	1.32 (0.02–76.6)	1.10 (0.02–62.2)	2.07 (0.04–108.4)	3.31 (0.05–235.4)	4.99 (0.07–351.1)
TZD	1.20 (0.54–2.66) I^2=0.0% 1 study	0.87 (0.73–1.04) I^2=0.0% 1 study		TZD	1.94 (0.01–542.9)	1.22 (0.00–342.7)	1.56 (0.01–465.9)	1.30 (0.02–77.4)	2.44 (0.01–679.9)	3.90 (0.01–1352.7)	5.89 (0.02–2023.9)
Met	1.18 (0.58–2.39) I^2=0.0% 4 studies	0.92 (0.77–1.10) I^2=0.0% 1 study	1.00 (0.02–50.6) I^2=0.0% 1 study	1.06 (0.89–1.26) I^2=0.0% 2 studies	Met	1.03 (0.02–54.5)	3.30 (0.05–233.4)	1.32 (0.02–76.0)	1.92 (0.03–115.6)	0.99 (0.02–51.4)	1.10 (0.49–2.45)
Met+TZD					0.97 (0.02–50.0) I^2=0.0% 1 study	Met+TZD	1.28 (0.00–372.4)	1.07 (0.02–61.2)	2.01 (0.01–543.2)	3.21 (0.01–1081.8)	4.84 (0.01–1618.5)
DPP4i+TZD	0.75 (0.35–1.61) I^2=0.0% 1 study			0.63 (0.36–1.09) I^2=0.0% 1 study			DPP4i+TZD	0.83 (0.01–52.1)	1.57 (0.03–91.3)	2.51 (0.40–15.8)	3.79 (0.62–23.2)
GLP-1RA		0.60 (0.16–2.21) I^2=0.0% 1 study			0.91 (0.49–1.68) I^2=0.0% 1 study			GLP-1RA	1.88 (0.03–106.2)	3.01 (0.04–229.1)	4.54 (0.06–341.9)
Placebo	1.10 (0.69–1.75) I^2=0.0% 8 studies		0.48 (0.01–24.4) I^2=0.0% 1 study	0.80 (0.02–42.4) I^2=0.0% 1 study	0.67 (0.04–11.0) I^2=0.0% 2 studies			1.18 (0.35–3.94) I^2=71.9 3 studies	Placebo	1.60 (0.02–113.9)	2.41 (0.03–169.9)
DPP4i+SGLT2i	0.30 (0.07–1.35) I^2=0.0% 1 study									DPP4i+SGLT2i	1.51 (0.62–3.69)
SGLT2i	0.51 (0.18–1.41) I^2=34.3% 3 studies								0.90 (0.49–1.68) I^2=0.0% 6 studies	0.66 (0.32–1.37) I^2=0.0% 1 study	SGLT2i